Pietro Giorgio Lovaglio, Morgan Ledroit, Anna Carannante, Fabio Rigat, Maurizio Comanducci, Cecilia Fazio, Raquel Abad, Giacomo Frosi, Jamie Findlow, Dominique A. Caugant, Ulrich Vogel, Muhamed-Kheir Taha, John J. Donnelly, Duccio Medini, Jay Lucidarme, Danielle Thompson, Davide Serruto, Martin Musilek, Maria Stella, Stefanie Gilchrist, Alessandro Muzzi, Paola Stefanelli, Ala Eddine Deghmane, Luca Orlandi, Eva Hong, Stefania Bambini, Ray Borrow, Heike Claus, Giuseppe Boccadifuoco, Julio A. Vázquez, Marzia Monica Giuliani, Paula Kriz, Rino Rappuoli, Jan Oksnes, Matthias Frosch, Mariagrazia Pizza, Institute of Hygiene and Microbiology [Wuerzburg], University of Würzburg, Institut Pasteur [Paris], Instituto de Salud Carlos III [Madrid] (ISC), Health Protection Agency [Manchester], Istituto Superiore di Sanita [Rome], Norwegian Institute of Public Health [Oslo] (NIPH), National Institute of Public Health [Prague], Novartis Vaccines and Diagnostics [Siena], Università degli Studi di Milano-Bicocca [Milano] (UNIMIB), Novartis Vaccines, Novartis Vaccines and Diagnostics., Vogel, U, Taha, M, Vazquez, J, Findlow, J, Claus, H, Stefanelli, P, Caugant, D, Kriz, P, Abad, R, Bambini, S, Carannante, A, Deghmane, A, Fazio, C, Frosch, M, Frosi, G, Gilchrist, S, Giuliani, M, Hong, E, Ledroit, M, Lovaglio, P, Lucidarme, J, Musilek, M, Muzzi, A, Oksnes, J, Rigat, F, Orlandi, L, Stella, M, Thompson, D, Pizza, M, Rappuoli, R, Serruto, D, Comanducci, M, Boccadifuoco, G, Donnelly, J, Medini, D, Borrow, R, Institut Pasteur [Paris] (IP), Istituto Superiore di Sanità (ISS), and Università degli Studi di Milano-Bicocca = University of Milano-Bicocca (UNIMIB)
Summary Background A novel multicomponent vaccine against meningococcal capsular group B (MenB) disease contains four major components: factor-H-binding protein, neisserial heparin binding antigen, neisserial adhesin A, and outer-membrane vesicles derived from the strain NZ98/254. Because the public health effect of the vaccine, 4CMenB (Novartis Vaccines and Diagnostics, Siena, Italy), is unclear, we assessed the predicted strain coverage in Europe. Methods We assessed invasive MenB strains isolated mainly in the most recent full epidemiological year in England and Wales, France, Germany, Italy, and Norway. Meningococcal antigen typing system (MATS) results were linked to multilocus sequence typing and antigen sequence data. To investigate whether generalisation of coverage applied to the rest of Europe, we also assessed isolates from the Czech Republic and Spain. Findings 1052 strains collected from July, 2007, to June, 2008, were assessed from England and Wales, France, Germany, Italy, and Norway. All MenB strains contained at least one gene encoding a major antigen in the vaccine. MATS predicted that 78% of all MenB strains would be killed by postvaccination sera (95% CI 63–90, range of point estimates 73–87% in individual country panels). Half of all strains and 64% of covered strains could be targeted by bactericidal antibodies against more than one vaccine antigen. Results for the 108 isolates from the Czech Republic and 300 from Spain were consistent with those for the other countries. Interpretation MATS analysis showed that a multicomponent vaccine could protect against a substantial proportion of invasive MenB strains isolated in Europe. Monitoring of antigen expression, however, will be needed in the future. Funding Novartis Vaccines and Diagnostics.